Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CT011 in Advanced Hepatocellular Carcinoma
NCT03884751Phase 1Completed
- Sponsor
- CARsgen Therapeutics
- Start
- Aug 2019
- Primary completion
- May 2021
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CT011 in hepatocellular carcinoma (HCC), sponsored by CARsgen Therapeutics. Primary endpoints: Dose-limiting toxicity at 28 days and Maximum tolerated dose at 28 days. Started Aug 2019; status: completed.
02
Drugs
CT011
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT03884751.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03884751.